Adaptimmune Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 10, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	10	7	138	180	239	586
Market Cap Growth	-85.22%	-95.00%	-23.47%	-24.70%	-59.17%	-29.79%
Enterprise Value	-2	30	26	44	62	372
Last Close Price	0.04	0.03	0.54	0.79	1.46	3.75
PE Ratio	0.39	0.27	-	-	-	-
PS Ratio	1.68	1.16	-	2.99	8.81	95.26
PB Ratio	0.31	0.22	10.57	4.56	2.92	2.84
P/TBV Ratio	0.31	0.22	30.53	4.60	2.94	2.86
P/FCF Ratio	-	-	-	-	-	271.82
P/OCF Ratio	-	-	-	-	-	54.60
EV/Sales Ratio	-	4.98	-	0.73	2.28	60.44
EV/FCF Ratio	-	-	-	-	-	172.44
Debt / Equity Ratio	0.44	0.44	5.70	0.64	0.28	0.12
Debt / FCF Ratio	-	-	-	-	-	11.82
Net Debt / Equity Ratio	-0.37	-0.37	-5.93	-3.08	-2.22	-1.67
Net Debt / EBITDA Ratio	0.21	0.21	0.48	1.01	1.15	2.21
Net Debt / FCF Ratio	0.10	0.10	1.10	0.84	1.06	-159.68
Asset Turnover	0.04	0.04	-	0.20	0.07	0.01
Inventory Turnover	-	-	-	97.02	126.15	78.45
Quick Ratio	1.64	1.64	2.56	2.66	3.76	6.45
Current Ratio	2.04	2.04	2.88	2.85	3.96	6.64
Return on Equity (ROE)	-346.65%	-346.65%	-673.20%	-187.61%	-114.97%	-57.78%
Return on Assets (ROA)	-25.87%	-25.87%	-40.77%	-26.71%	-25.67%	-22.03%
Return on Capital Employed (ROCE)	-155.90%	-155.90%	-95.00%	-62.30%	-62.00%	-39.90%
Earnings Yield	253.60%	365.76%	-52.15%	-63.22%	-69.17%	-26.99%
FCF Yield	-1230.40%	-1774.62%	-50.78%	-80.82%	-71.60%	0.37%
Buyback Yield / Dilution	-11.11%	-7.97%	-25.48%	-24.73%	-3.47%	-9.37%